NPS Pharmaceuticals, Inc., a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced that the European Commission has granted orphan drug designation to Natpara (recombinant human parathyroid hormone (rhPTH[1-84]) for the treatment of hypoparathyroidism.

Read the original:
NPS Pharmaceuticals’ Natpara gets orphan drug designation for treatment of hypoparathyroidism

Scroll to Top